Ignite Creation Date:
2025-12-24 @ 5:20 PM
Ignite Modification Date:
2026-02-23 @ 3:01 PM
Study NCT ID:
NCT02404350
Status:
COMPLETED
Last Update Posted:
2020-04-20
First Post:
2015-03-16
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-08-31
Start Date Type:
ACTUAL
Primary Completion Date:
2017-08-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-01-24
Completion Date Type:
ACTUAL
First Submit Date:
2015-03-16
First Submit QC Date:
None
Study First Post Date:
2015-03-31
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-07-19
Results First Submit QC Date:
None
Results First Post Date:
2019-06-28
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-04-09
Last Update Post Date:
2020-04-20
Last Update Post Date Type:
ACTUAL